Sarah Strickland1,2, Carlos Parra-Herran3,4. 1. Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada. 2. The Ottawa Hospital and Eastern Ontario Regional Laboratory Association, Ottawa, Ontario, Canada. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 4. Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
Abstract
AIMS: The distinction between primary ovarian mucinous tumours and appendiceal mucinous neoplasms metastatic to the ovary can be challenging, given the overlap of morphological features and immunohistochemical expression of traditional markers. Special AT-rich sequence-binding protein 2 (SATB2) has recently been described as a sensitive and specific marker of colorectal epithelium. This study was to determine its expression in appendiceal mucinous tumours and its role in their distinction from ovarian neoplasms. METHODS AND RESULTS: Immunohistochemistry was performed in tissue microarrays from 32 primary appendiceal mucinous tumours (25 low-grade appendiceal mucinous neoplasms and seven adenocarcinomas) and 40 ovarian mucinous neoplasms (20 borderline tumours and 20 adenocarcinomas). Stains were interpreted as positive or negative by scoring intensity and distribution. SATB2 was positive in 93.8% of appendiceal tumours and in only one ovarian tumour; SATB2 was 97.5% specific for appendiceal origin. CK20, CDX2 and MUC2 were strongly and diffusely positive in appendiceal tumours; ovarian tumours were also positive, but with a patchy distribution and mild intensity. CK7 was expressed in 97.5% of ovarian tumours and in 31.2% of appendiceal tumours. PAX8 was positive in 70% of ovarian tumours, and negative in all appendiceal lesions. CONCLUSIONS: SATB2 is frequently expressed in appendiceal mucinous neoplasms. In the context of a mucinous neoplasm involving the ovary, any SATB2 positivity should raise the possibility of appendiceal origin. Expression of CK20, CDX2 and MUC2 supports appendiceal origin only when diffuse and strong. These and other markers, such as CK7 and PAX8, are recommended in the work-up of ovarian mucinous tumours with any clinical or pathological features suggestive of secondary origin.
AIMS: The distinction between primary ovarian mucinous tumours and appendiceal mucinous neoplasms metastatic to the ovary can be challenging, given the overlap of morphological features and immunohistochemical expression of traditional markers. Special AT-rich sequence-binding protein 2 (SATB2) has recently been described as a sensitive and specific marker of colorectal epithelium. This study was to determine its expression in appendiceal mucinous tumours and its role in their distinction from ovarian neoplasms. METHODS AND RESULTS: Immunohistochemistry was performed in tissue microarrays from 32 primary appendiceal mucinous tumours (25 low-grade appendiceal mucinous neoplasms and seven adenocarcinomas) and 40 ovarian mucinous neoplasms (20 borderline tumours and 20 adenocarcinomas). Stains were interpreted as positive or negative by scoring intensity and distribution. SATB2 was positive in 93.8% of appendiceal tumours and in only one ovarian tumour; SATB2 was 97.5% specific for appendiceal origin. CK20, CDX2 and MUC2 were strongly and diffusely positive in appendiceal tumours; ovarian tumours were also positive, but with a patchy distribution and mild intensity. CK7 was expressed in 97.5% of ovarian tumours and in 31.2% of appendiceal tumours. PAX8 was positive in 70% of ovarian tumours, and negative in all appendiceal lesions. CONCLUSIONS:SATB2 is frequently expressed in appendiceal mucinous neoplasms. In the context of a mucinous neoplasm involving the ovary, any SATB2 positivity should raise the possibility of appendiceal origin. Expression of CK20, CDX2 and MUC2 supports appendiceal origin only when diffuse and strong. These and other markers, such as CK7 and PAX8, are recommended in the work-up of ovarian mucinous tumours with any clinical or pathological features suggestive of secondary origin.
Authors: Zaibo Li; Rachel Roth; Jonathan B Rock; Amy Lehman; William L Marsh; Adrian Suarez; Wendy L Frankel Journal: Am J Clin Pathol Date: 2017-05-01 Impact factor: 2.493
Authors: Nicola S Meagher; Linyuan Wang; Peter F Rambau; Maria P Intermaggio; David G Huntsman; Lynne R Wilkens; Mona A El-Bahrawy; Roberta B Ness; Kunle Odunsi; Helen Steed; Esther Herpel; Michael S Anglesio; Bonnie Zhang; Neil Lambie; Anthony J Swerdlow; Jan Lubiński; Robert A Vierkant; Ellen L Goode; Usha Menon; Aleksandra Toloczko-Grabarek; Oleg Oszurek; Sanela Bilic; Aline Talhouk; Montserrat García-Closas; Qin Wang; Adeline Tan; Rhonda Farrell; Catherine J Kennedy; Mercedes Jimenez-Linan; Karin Sundfeldt; John L Etter; Janusz Menkiszak; Marc T Goodman; Paul Klonowski; Yee Leung; Stacey J Winham; Kirsten B Moysich; Sabine Behrens; Tomasz Kluz; Robert P Edwards; Jacek Gronwald; Francesmary Modugno; Brenda Y Hernandez; Christine Chow; Linda E Kelemen; Gary L Keeney; Michael E Carney; Yanina Natanzon; Gregory Robertson; Raghwa Sharma; Simon A Gayther; Jennifer Alsop; Hugh Luk; Chloe Karpinskyj; Ian Campbell; Peter Sinn; Aleksandra Gentry-Maharaj; Penny Coulson; Jenny Chang-Claude; Mitul Shah; Martin Widschwendter; Katrina Tang; Minouk J Schoemaker; Jennifer M Koziak; Linda S Cook; James D Brenton; Frances Daley; Björg Kristjansdottir; Constantina Mateoiu; Melissa C Larson; Paul R Harnett; Audrey Jung; Anna deFazio; Kylie L Gorringe; Paul D P Pharoah; Parham Minoo; Colin Stewart; Oliver F Bathe; Xianyong Gui; Paul Cohen; Susan J Ramus; Martin Köbel Journal: Mod Pathol Date: 2019-06-25 Impact factor: 8.209